Latest news with #ArunKejriwal
Mint
14-07-2025
- Business
- Mint
Anthem Biosciences IPO day 1 Live: GMP, subscription status, review, other details. Buy or not?
Anthem Biosciences IPO: The initial public offering (IPO) of Anthem Biosciences Limited has hit the Indian primary market today. The public issue will remain open until 16 July 2025. This means the book build issue will remain open from Monday to Wednesday. The company promoters have declared the Anthem Biosciences IPO price band at ₹ 540 to ₹ 570 per equity share. The company aims to raise ₹ 3,395 crore from this initial offer, which is entirely offer-for-sale (OFS). Anthem Biosciences IPO is proposed for listing on the BSE and the NSE. The company's shares are available in the grey market before the Anthem Biosciences IPO subscription opening. According to market observers, shares of the company are available at a premium of ₹ 101 in the grey market today. 1] Anthem Biosciences IPO GMP: According to market observers, shares of the company are available at a premium of ₹ 101 in the grey market today. 2] Anthem Biosciences IPO subscription date: The public issue has opened today and will remain open until 16 July 2025. 3] Anthem Biosciences IPO price: The company has declared a price band of ₹ 540 to ₹ 570 per equity share. 4] Anthem Biosciences IPO size: The company aims to raise ₹ 3,395 crore from this initial public offering (ipo), which is entirely offer-for-sale (OFS). Photo: Courtesy mintgenie 5] Anthem Biosciences IPO lot size: Bidders can apply in lots, and one lot will comprise 26 company shares. 6] Anthem Biosciences IPO allotment date: The most likely date for share allotment is 17 July 2025. 7] Anthem Biosciences IPO registrar: KFin Technologies Ltd has been appointed registrar of the public issue. 8] Anthem Biosciences IPO lead managers: JM Financial, Citigroup Global Markets, JP Morgan India, and Nomura Financial Advisors have been appointed lead managers of the public offer. 9] Anthem Biosciences IPO listing date: The most likely date for share debut is 21 July 2025. 10] Anthem Biosciences IPO review: Advising invstors to apply for the book-build issue, Arun Kejriwal, Founder of Kejriwal Research and Investment Services, said, "The company is a CRDMO – contract research development and manufacturing organization with fully integrated operations spanning across drug discovery, development and manufacturing with integrated New Chemical entity and New Biological Entity Capabilities. The company reported revenues of ₹ 1,844.55 crores and a PAT of ₹ 451 crores for the year ended March 25. The net margins are a healthy 23.4%. The EPS is ₹ 8.04. The PE multiple on a fully diluted basis is at 67.16-70.90," adding, "The key takeaway from this offer for sale is that the promoter founder of the company would continue to hold over 52% of the company and is not selling a single share in the entirely an offer for sale issue. This is a big comforting factor for investors nowadays, who are very wary of the entire offer for sale issues." Anand Rathi has also assigned a 'subscribe' tag to the public issue, saying, "The company has shown a profitable track record against its peers and intends to maintain it by leveraging its integrated manufacturing and technological capabilities by focusing on building complex speciality ingredients, peptides, probiotics, etc. On valuation parse, based on the annualised FY25, it is seeking PE of 70.6 times, and the post-issue market cap comes at ₹ 3,18,673 Mn. With this, the issue is fairly priced. We believe the company has the potential to continue to grow its revenue and profitability ratios compared to its peers. Hence, we give a "SUBSCRIBE" rating for the issue." Disclaimer: The views and recommendations above are those of individual analysts or brokerage companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Mint
01-07-2025
- Business
- Mint
Why does the Indian stock market expect better Q1FY26 results? Explained with four key reasons
Q1FY26 results preview: After almost four quarters of unimpressive earnings, hopes are high that the Q1FY26 earnings will cheer the Indian stock market up. FY25 was a mixed year for Indian corporates, with earnings witnessing widespread downgrades. Soft demand and tepid capital expenditure dragged the overall corporate performance during the last financial year. According to Nuvama Research, the aggregate profit after tax (PAT) of BSE 500 companies (excluding oil marketing companies) saw a modest growth of 10 per cent year-on-year in Q4FY25, and 9 per cent for the full FY25. This was down from a solid 21 per cent growth in FY24. Here are four key factors that indicate Indian Inc.'s performance in Q1FY26 will be better: The Nifty 50 delivered a 4 per cent year-on-year growth in Q1FY25, reporting the first quarter of single-digit EBITDA growth in four years. Experts believe the low base effect will play its part in Q1FY26. "Q1FY26 may be a better year-on-year, mainly because of the low base effect. Also, a lot of cyclical sectors, such as metals, oil and gas, are expected to do well," said Pankaj Pandey, the head of research at ICICI Securities. RBI rate cuts are a key indicator that suggests Indian corporate earnings will be better in FY26 than last year. "The results season for the April to June 2025 quarter will kick in. The larger section of companies is expected to benefit from three successive rate cuts by the RBI. The impact of the first two cuts will be felt on corporates' bottom lines, and this should help in better earnings," said Arun Kejriwal, Founder of Kejriwal Research and Investment Services. "Revenues or topline growth is expected when the liquidity infused by RBI through the CRR cut of 100 basis points in four tranches of 25 basis points each kicks in to match the festival season," said Kejriwal. India's gross collection of goods and services tax (GST) hit an all-time high of ₹ 22.08 lakh crore in FY25, up 9.4 per cent year-on-year, according to an official statement on 30 June. The record GST collection suggests that India's economic activity remained strong last financial year, which should translate into improved corporate earnings. India's inflation eased steadily in FY25, averaging around 4.8 per cent. The relatively moderate price rise meant that companies faced less pressure from input cost inflation. This environment likely supported better operating margins, contributing to improved corporate profitability. Read all market-related news here Read more stories by Nishant Kumar Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions, as market conditions can change rapidly, and circumstances may vary.
Mint
25-06-2025
- Business
- Mint
ArisInfra Solutions share price plunges over 22% after weak listing; Should you buy, sell or hold?
Arisinfra Solutions share price plunged after making a weak debut in the Indian stock market today. Arisinfra Solutions shares declined over 22% from its issue price on Wednesday after listing at discount. Arisinfra Solutions shares were listed at ₹ 205 apiece on the NSE, a discount of 7.66% from its issue price of ₹ 222. On BSE, the stock was listed with a 5.81% discount at ₹ 209.10 apiece. Following the weak listing, selling pressure intensified, dragging Arisinfra Solutions share price down to ₹ 172.65 on the BSE — a decline of 22.23% from the issue price. Arisinfra Solutions IPO listing largely in line with Street expectations as market analysts had anticipated a tepid listing, citing muted interest in the company's initial public offering (IPO) and a flat grey market premium (GMP) leading up to the debut. Analysts attributed the weak share listing to the muted response received for ArisInfra Solutions IPO and overall lacklustre investor demand. 'ArisInfra Solutions shares made a weak debut on the stock exchanges, listing at a discount after receiving a lukewarm response to its IPO. The stock declined post-listing amid subdued momentum. Given the lackluster listing and ongoing volatility, IPO investors may consider exiting their positions, while maintaining a stop loss in the range of ₹ 180 – ₹ 182,' said Arun Kejriwal, founder of Kejriwal Research and Investment Services. While the current price levels may appear attractive to new investors, it is advisable to adopt a wait-and-watch approach until the stock price shows signs of stabilisation, he added. Arisinfra Solutions IPO was subscribed 2.65 times in total. The retail investors segment was booked 5.59 times, the Non Institutional Investors (NII) portion was subscribed 3.14 times, and the Qualified Institutional Buyers (QIBs) segment was booked 1.42 times. At 2:10 PM, ArisInfra Solutions share price was trading at ₹ 173.10 apiece on the BSE, down 17.22% from its listing price, and down 22.03% from its issue price. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Mint
04-06-2025
- Business
- Mint
Scoda Tubes share price hits 5% upper circuit after flat listing. Should you, buy, hold or sell?
Scoda Tubes share price was locked in at 5% upper circuit on Wednesday after the stock made a flat debut in the Indian stock market. Scoda Tubes shares jumped 5% from its listing price to a high of ₹ 146.95 apiece on the BSE. Scoda Tubes shares made a flat debut on Dalal Street as the stainless-steel tubes and pipes manufacturer's stock was listed at ₹ 140 per share, which is equal to its issue price of ₹ 140 per share. The stock declined after the listing and fell to an intraday low of ₹ 136.00 apiece on the BSE. However, buying momentum in Scoda Tubes shares intensified, and the stock jumped as much as 4.96% from its listing price to freeze at upper circuit of ₹ 146.95 apiece. Scoda Tubes IPO listing date was today, 4 June 2025. Amid high volatility here's what analysts suggest for Scoda Tubes shares after listing: Commenting on the listing performance, Arun Kejriwal, Founder of Kejriwal Research and Investment Services, said, 'This was an unusual listing. Despite strong oversubscription, the shares listed flat and then fell before hitting the upper circuit. This indicates poor screen management and serves as a reminder to investors who rely heavily on grey market premiums (GMPs). The GMP can often be misleading, and in this case, the euphoria around the IPO quickly faded.' Since the IPO proceeds are earmarked for capital expenditure, which will take at least 12 months to show results, investors should consider exiting and booking whatever profits are available in the short term, Kejriwal added. Scoda Tubes is currently valued at a price-to-earnings (P/E) ratio of 30.43x and a price-to-book (P/B) ratio of 8.76x based on FY24 financials—broadly in line with industry peers. Mahesh M Ojha, AVP – Research and Business Development at Hensex Securities Pvt Ltd, suggests a more patient approach. 'Investors who were allotted shares during the IPO may consider holding Scoda Tubes for the medium to long term,' he said. At 1:20 PM, Scoda Tubes share price was still locked at 5% upper circuit of ₹ 146.95 apiece on the BSE. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Mint
29-05-2025
- Business
- Mint
IPO watch: Why Leela Hotels, Aegis Vopak Terminals fail to create euphoria despite large fresh offers
After a prolonged lull, the Indian primary market regained momentum in May, with six mainboard companies launching their initial public offerings (IPOs). The earlier slowdown in IPO activity was largely attributed to weak global sentiment driven by concerns over the economic fallout from the US-China trade war, exacerbated by tariff policies introduced by US President Donald Trump. As macroeconomic tensions began to ease, IPO activity saw a resurgence. On May 26, Schloss Bangalore Ltd — the operator of luxury hospitality brand 'The Leela' — and Aegis Vopak Terminals launched their respective IPOs. The ₹ 3,500-crore Leela Hotels IPO comprised a fresh issue of 5.75 crore equity shares worth ₹ 2,500 crore and an offer-for-sale (OFS) of 2.30 crore shares amounting to ₹ 1,000 crore. Aegis Vopak Terminals IPO was a ₹ 2,800 crore offer, entirely consisting of a fresh issue of 11.91 crore shares. Despite the sizable fresh capital offerings, both IPOs failed to replicate the enthusiasm seen in recent listings such as Borana Weaves IPO and Belrise Industries IPO. Leela Hotels IPO was subscribed 4.50 times overall, receiving bids for 20.96 crore shares against the 4.66 crore shares on offer. The Qualified Institutional Buyers (QIB) segment led the demand, subscribing 7.46 times, while the Non-Institutional Investor (NII) and retail categories saw relatively muted interest at 1.02 times and 0.83 times, respectively. Aegis Vopak Terminals IPO garnered even less interest, with an overall subscription of 2.09 times. While the QIB portion was subscribed 3.30 times, the retail and NII segments fell short, at 0.77 times and 0.56 times, respectively. Market analysts attribute the subdued response primarily to steep valuations and uncertain market sentiment. Schloss Bangalore reported a revenue of ₹ 1,300.6 crore in FY25, growing at a CAGR of 23% from FY23 to FY25. The company posted a net profit of ₹ 48 crore in FY25, largely supported by a higher average room rate (ARR) and reduced debt-related stress. However, at an IPO price of ₹ 435 per share, the company's valuation stood at an elevated price-to-earnings (P/E) ratio of 220.8x, significantly higher than industry peers. Aegis Vopak Terminals, priced at ₹ 235 per share, posted a net profit of ₹ 86.54 crore in FY24 after a marginal loss in FY23. Yet, analysts noted the valuation was stretched, with the issue priced at 60x EV/EBITDA and 258x P/E (annualized FY25 earnings). Arun Kejriwal, Founder of Kejriwal Research and Investment Services, flagged two key concerns: 'The pricing of both IPOs was high, and the market lacked clarity on the companies' forward-looking growth drivers.' He added that the muted retail and HNI participation contrasted with more active institutional involvement, which largely sustained the subscription figures. 'In the case of Leela Hotels IPO, a P/E of over 200 implies the company is generating minimal profit per share. While expansion of hotel capacity is on the cards, the resultant growth will not materialize in the short term.' For Aegis Vopak Terminals, Kejriwal noted that many investors remained unsure about the company's ability to generate commensurate profit given its current revenue and lofty market capitalization. Adding context to the tepid response, he pointed to the listing performance of Belrise Industries. 'The final day for these two IPOs coincided with the Belrise Industries IPO listing. Initially, Belrise Industries shares were expected to debut with a 22-23% premium, but it ultimately listed at just an 11% premium. As expectations of profit from this company did not materialize, investors became more cautious regarding these two issues as well.' Prashanth Tapse, Senior Vice President (Research) at Mehta Equities, echoed similar sentiments. 'Investor appetite from retail and HNI segments remained subdued, which is justified given the rich valuations and cautious market mood.' The trends in the grey market premium (GMP) for both these IPOs also remain muted. While Leela Hotels IPO GMP today was ₹ 6 per share, or 1.4%, Aegis Vopak Terminals IPO GMP was Re 1 per share, or 0.5%, market experts said. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
